Communiqués Takeda Pharmaceutical Company Limited

Actions

4502

JP3463000004

Marché Fermé - Japan Exchange Autres places de cotation 08:00:00 31/05/2024			Varia. 5j.	Varia. 1 janv.
4 173 ^JPY	+1,88 %		+0,94 %	+2,94 %

31/05	Takeda Pharmaceutical annonce que l'ADAMTS13 recombinant a reçu la recommandation d'approbation du CHPM de l'Agence européenne des médicaments	MT
31/05	Takeda reçoit un avis positif du CHMP pour l'ADAMTS13 recombinant (rADAMTS13) dans le purpura thrombocytopénique thrombotique congénital (PTTC)	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)	31/05	BU
Takeda Pharmaceutical : Other items which are provided electronically	29/05	PU
TAKEDA PHARMACEUTICAL : Form 6-K	21/05	PU
Takeda Canada Inc. concludes Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for LIVTENCITY® (maribavir) for the treatment of adults with a post-transplant cytomegalovirus (CMV) infection	16/05	AQ
Takeda to Present Oncology Portfolio and Pipeline Data at the 2024 ASCO Annual Meeting	14/05	BU
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease	13/05	BU
Takeda Announces Enterprise-wide Program to Support Growth and Deliver Core Operating Profit Margin Improvement	10/05	AQ
Takeda Pharmaceutical, Announces full-year 2023 results and outlook for 2024 Emphasizes commitment to late-stage pipeline development and core operating margin improvement	10/05	AQ
Takeda annonce ses résultats pour l’exercice 2023 et ses perspectives pour l’exercice 2024, confirmant son engagement en faveur du développement d’un portefeuille de produits à un stade avancé et de l’augmentation de la marge bénéficiaire...	10/05	BU
Takeda Pharmaceutical : FINANCIAL APPENDIX - Form 6-K	09/05	PU
Takeda Pharmaceutical : FY2023 (April 2023-March 2024) Quarter 4 Presentation	09/05	PU
Takeda Pharmaceutical : FY2023 (April 2023-March 2024) Quarter 4 Quarterly Financial Report	09/05	PU
Takeda Pharmaceutical : FY2023 (April 2023-March 2024) Quarter 4 Quarterly Highlights Infographic	09/05	PU
Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion	09/05	BU
Takeda Pharmaceutical Company Limited: Takeda Announces Enterprise-wide Program to Support Growth and Deliver Core Operating Profit Margin Improvement	09/05	EQ
HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda	29/04	AQ
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer	26/04	BU
U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO for Maintenance Therapy in Moderately to Severely Active Crohn's Disease	19/04	AQ
Takeda to Hold Fiscal Year 2023 Earnings Call on May 9	19/04	AQ
U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease	19/04	BU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Takeda Pharmaceutical Company Limited

Actions

4502

JP3463000004

Communiqués

Filtres